Skip to Content

'
Marjorie C. Green

Present Title & Affiliation

Primary Appointment

Associate Professor of Medicine and Internist (non-tenured track), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1995 University of Texas Medical Branch at Galveston, Galveston, TX, MD, Medicine
1991 University of Notre Dame, South Bend, IN, BA, History

Postgraduate Training

7/1998-6/2001 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff, M.D.
7/1998-6/2001 Clinical Fellowship, Medical Hematology, University of Texas Health Science Center at Houston/The University of Texas MD Anderson Cancer Center, Houston, TX, H. Junejia, M.D.
7/1995-6/1998 Internship and Residency, University of Virginia Health Sciences Center, Charlottesville, VA, Michael Scheld, M.D.

Board Certifications

12/2021 American Board of Internal Medicine, Medical Onc
12/2008 American Board of Internal Medicine, Internal Med

Experience/Service

Administrative Appointments/Responsibilities

Associate Clinical Medical Director, Nellie B. Connally Breast Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-8/2012

Selected Publications

Peer-Reviewed Original Research Articles
1. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710-6, 5/2012. e-Pub 1/29/2012. PMID: 22285778.
2. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. J Clin Oncol 30(9):930-5, 3/20/2012. e-Pub 2/13/2012. PMID: 22331946.
3. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of Anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila) 5(2):276-82, 2/2012. e-Pub 11/18/2011. PMID: 22102688.
4. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and-negative cancers. J Clin Oncol 28(28):4316-23, 10/1/2010. e-Pub 8/30/2010. PMID: 20805453.
5. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28(25):3917-21, 9/1/2010. e-Pub 8/2/2010. PMID: 20679610.
6. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer 103(9):1331-4, 2010. e-Pub 9/2010. PMID: 20877352.
7. Green MC, Esteva FJ, Hortobagyi GN. Neoadjuvant chemotherapy. Breast Dis 21. e-Pub 9/3/2009. PMID: 19729775.
8. Ma J, Costelloe CM, Madewell JE, Hortobagyi GN, Green MC, Cao G, Sun F, Kundra V. Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging 29(5):1154-1162, 5/2009. PMID: 19388121.
9. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621-7, 4/2009. e-Pub 1/2009. PMCID: PMC2722369.
10. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27(2):220-6, 1/10/2009. e-Pub 12/1/2008. PMID: 19047281.
11. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020-5, 7/2008. e-Pub 7/2008. PMID: 18667396.
12. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations. Ann Oncol 19(10):1713-9, 5/2008. e-Pub 5/2008. PMID: 18515258.
13. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-81, 3/10/2008. e-Pub 2/4/2008. PMID: 18250347.
14. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108(2):183-190, 3/2008. e-Pub 4/28/2007. PMID: 17468948.
15. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-22, 10/1/2007. e-Pub 9/4/2007. PMID: 17785706.
16. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-8, 8/15/2007. PMID: 17699874.
17. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-33, 1/1/2007. PMID: 17200359.
18. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13(11):1443-9, 11/2006. e-Pub 9/21/2006. PMID: 17028770.
19. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-92, 9/1/2005. e-Pub 8/8/2005. PMID: 16087943.
20. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated Protein Tau: A Marker of Paclitaxel Sensitivity in Breast Cancer. Proc Natl Acad Sci U S A 102(23):8315-20, 6/7/2005. e-Pub 5/24/2005. PMCID: PMC1149405.
21. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 6/1/2005. e-Pub 2/28/2005. PMID: 15738535.
22. Ibrahim N, Francis D, Booser D, Thomas E, Theriault R, Pusztai L, Green M, Arun B, Giordano S, Cristofanilli M, Frye D, Smith T, Hunt K, Singletary E, Sahin A, Ewer M, Buchholz T, Berry D, Hortobagyi G. Herceptin plus chemotherapy combination in preoperative regimen may offer clinical benefit in early stage breast cancer. Cancer Biol Ther 4(5):3-4, 2005.
23. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100(7):1365-73, 4/1/2004. PMID: 15042669.
24. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total rna yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, 6/15/2003. PMID: 12784330.
25. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 26(4):269-86, 2000. PMID: 10913382.

Invited Articles
1. Green MC, Esteva FJ, Hortobagyi GN. Neoadjuvant Chemotherapy. Breast Dis 21:23-31, 2004. PMID: 15687719.
2. Green MC, Hortobagyi GN. Adjuvant Chemotherapy for Breast Cancer. Langenbecks Arch Surg 387(3-4):109-116, 7/2002. PMID: 12269263.
3. Green M, Hortobagyi GN. Neoadjuvant Chemotherapy for Operable Breast Cancer. Oncology (Williston Park) 16(7):871-89, 7/2002. PMID: 12164555.

Last updated: 11/1/2012